Migration of the epidermal over the dermal component (epiboly) in a bilayered bioengineered skin construct

Tissue Engineering

Volumn 13, Issue 1, 2007, Pages 21-28

  Falanga, Vincent ^a,b   Butmarc, Janet ^a   Cha, Jisun ^a   Yufit, Tatyana ^a   Carson, Polly ^a  

^a ROGER WILLIAMS MEDICAL CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; BIOCHEMISTRY; BIOMEDICAL ENGINEERING; BIOPSY; CELLS; GROWTH KINETICS; NEONATAL MONITORING;

BIOLOGICAL PROPERTIES; DERMAL COMPONENT; HUMAN NEONATAL KERATINOCYTES; SERUM-FREE MEDIUM;

DERMATOLOGY;

ALPHAVBETA5 INTEGRIN; CYTOKINE; EPIDERMAL GROWTH FACTOR; GROWTH FACTOR; INTERLEUKIN 1ALPHA; KALININ; NEUTRALIZING ANTIBODY; TRANSFORMING GROWTH FACTOR BETA1; VERY LATE ACTIVATION ANTIGEN 3; VITRONECTIN;

ANALYTIC METHOD; ANTIBODY DETECTION; ARTIFICIAL SKIN; BILAYER MEMBRANE; BILAYERED BIOENGINEERED LIVING SKIN CONSTRUCT; BIOENGINEERING; CELL MIGRATION; COMPUTER ANALYSIS; COMPUTERIZED PLANIMETRY; CONFERENCE PAPER; CULTURE MEDIUM; DERMIS; DOWN REGULATION; EPIDERMIS; FIBROBLAST; HEALING; HISTOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; NEWBORN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PUNCH BIOPSY; SKIN INJURY;

ANIMALS; CATTLE; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; COLLAGEN; DERMIS; EPIDERMIS; FIBROBLASTS; HUMANS; KERATINOCYTES; SKIN, ARTIFICIAL; TISSUE ENGINEERING;

EID: 33846648423     PISSN: 10763279     EISSN: None     Source Type: Journal    
DOI: 10.1089/ten.2006.0148     Document Type: Conference Paper

References (40)

1. Falanga, V. Wound healing and its impairment in the diabetic foot. Lancet 366, 1736, 2005.
2. Martin, P. Wound healing-aiming for perfect skin regeneration. Science 276, 75, 1997.
3. Thomas, D.W., and K.G. Harding. Wound healing. Br J Surg 89, 1203, 2002.
4. Ehrlich, H.P. Understanding experimental biology of skin equivalent: from laboratory to clinical use in patients with burns and chronic wounds. Am J Surg 187, 29S, 2004.
5. Providence, K.M., et al. Epithelial monolayer wounding stimulates binding of USF-1 to an E-box motif in the plasminogen activator inhibitor type 1 gene. J Cell Sci 115, 3767, 2002.
6. Daher, A., et al. Growth, differentiation and senescence of normal human urothelium in an organ-like culture. Eur Urol 45, 799, 2004.
7. Donaldson, D.J., J.T. Mahan, and G.N. Smith, Jr. Newt epidermal cell migration in vitro and in vivo appears to involve Arg-Gly-Asp-Ser receptors. J Cell Sci, 87, 525, 1987.
8. Regauer, S., and C.C. Compton. Cultured keratinocyte sheets enhance spontaneous re-epithelialization in a dermal explant model of partial-thickness wound healing. J Invest Dermatol 95, 341, 1990.
9. Wong, P., and P.A. Coulombe. Loss of keratin 6 (K6) proteins reveals a function for intermediate filaments during wound repair. J Cell Biol 163, 327, 2003.
10. Falanga, V., et al. Wounding of bioengineered skin: cellular and molecular aspects after injury. J Invest Dermatol 119, 653, 2002.
11. Kim, J.P., et al. Vitronectin-driven human keratinocyte locomotion is mediated by the alpha v beta 5 integrin receptor. J Biol Chem 269, 26926, 1994.
12. Stenn, K.S. Epibolin: a protein of human plasma that supports epithelial cell movement. Proc Natl Acad Sci U S A 78, 6907, 1981.
13. Ruoslahti, E., et al. Purification and characterization of vitronectin. Methods Enzymol 144, 430, 1987.
14. Sabolinski, M.L., et al. Cultured skin as a 'smart material' for healing wounds: experience in venous ulcers. Biomaterials 17, 311, 1996.
15. Nahm, W.K., et al. Significance of N-methyl-D-aspartate (NMDA) receptor-mediated signaling in human keratinocytes. J Cell Physiol 200, 309, 2004.
16. Geer, D.J., D.D. Swartz, and S.T. Andreadis. In vivo model of wound healing based on transplanted tissue-engineered skin. Tissue Eng 10, 1006, 2004.
17. Kurokawa, I., et al. Cytokeratin, filaggrin, and p63 expression in reepithelialization during human cutaneous wound healing. Wound Repair Regen 14, 38, 2006.
18. Kim, S., P. Wong, and P.A. Coulombe. A keratin cytoskeletal protein regulates protein synthesis and epithelial cell growth. Nature 441, 362, 2006.
19. Quesenberry, P., et al. Marrow stem cell potential within a continuum. Ann N Y Acad Sci 996, 209, 2003.
20. Erdag, G., et al. FGF-7 expression enhances the performance of bioengineered skin. Mol Ther 10, 76, 2004.
21. Geer, D.J., D.D. Swartz, and S.T. Andreadis. Biomimetic delivery of keratinocyte growth factor upon cellular demand for accelerated wound healing in vitro and in vivo. Am J Pathol 167, 1575, 2005.
22. Mirastschijski, U., et al. Epithelial regeneration from bioengineered skin explants in culture. Br J Dermatol 154, 42, 2006.
23. Falanga, V., et al. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol 134, 293, 1998.
24. Falanga, V., and M. Sabolinski. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 7, 201, 1999.
25. Veves, A., et al. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care 24, 290, 2001.
26. Griffiths, M., et al. Survival of Apligraf in acute human wounds. Tissue Eng 10, 1180, 2004.
27. Phillips, T.J., et al. The longevity of a bilayered skin substitute after application to venous ulcers. Arch Dermatol 138, 1079, 2002.
28. Falabella, A.F., et al. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol 136, 1225, 2000.
29. Fivenson, D.P., L. Scherschun, and L.V. Cohen. Apligraf in the treatment of severe mitten deformity associated with recessive dystrophic epidermolysis bullosa. Plast Reconstr Surg 112, 584, 2003.
30. Guerret, S., et al. Long-term remodeling of a bilayered living human skin equivalent (Apligraf) grafted onto nude mice: immunolocalization of human cells and characterization of extracellular matrix. Wound Repair Regen 11, 35, 2003.
31. Still, J., et al. The use of a collagen sponge/living cell composite material to treat donor sites in burn patients. Burns 29, 837, 2003.
32. Chen, J.D., et al. Epidermal growth factor (EGF) promotes human keratinocyte locomotion on collagen by increasing the alpha 2 integrin subunit. Exp Cell Res 209, 216, 1993.
33. Chen, J.D., et al. Interleukin-1 alpha stimulates keratinocyte migration through an epidermal growth factor/transforming growth factor-alpha-independent pathway. J Invest Dermatol 104, 729, 1995.
34. Sarret, Y., et al. Human keratinocyte locomotion: the effect of selected cytokines. J Invest Dermatol 98, 12, 1992.
35. Ashcroft, G.S., et al. Mice lacking Smad3 show accelerated wound healing and an impaired local inflammatory response. Nat Cell Biol 1, 260, 1999.
36. Falanga, V., et al. Full-thickness wounding of the mouse tail as a model for delayed wound healing: accelerated wound closure in Smad3 knock-out mice. Wound Repair Regen 12, 320, 2004.
37. Hosokawa, R., et al. Functional significance of Smad2 in regulating basal keratinocyte migration during wound healing. J Invest Dermatol 125, 1302, 2005.
38. Minor, K.H., et al. A mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis. J Biol Chem 280, 28711, 2005.
39. Ruoslahti, E. The RGD story: a personal account. Matrix Biol 22, 459, 2003.
40. Takahashi, T., et al. Plasminogen activator inhibitor type 1 promotes fibrosarcoma cell migration by modifying cellular attachment to vitronectin via alpha(v)beta(5) integrin. Semin Thromb Hemost 31, 356, 2005.